309 related articles for article (PubMed ID: 7879258)
21. Evidence that HLA class II disparity is required for the induction of renal allograft enhancement by donor-specific blood transfusions in man.
Lazda VA; Pollak R; Mozes MF; Barber PL; Jonasson O
Transplantation; 1990 Jun; 49(6):1084-7. PubMed ID: 2360251
[TBL] [Abstract][Full Text] [Related]
22. Donor-specific transfusions have long-term beneficial effects for human renal allografts.
Flye MW; Burton K; Mohanakumar T; Brennan D; Keller C; Goss JA; Sicard GA; Anderson CB
Transplantation; 1995 Dec; 60(12):1395-401. PubMed ID: 8545863
[TBL] [Abstract][Full Text] [Related]
23. Living donor transplants.
Cecka JM
Clin Transpl; 1995; ():363-77. PubMed ID: 8794280
[TBL] [Abstract][Full Text] [Related]
24. The impact of gender and age matching for long-term graft survival in living donor renal transplantation.
Kwon OJ; Kwak JY; Kang CM
Transplant Proc; 2005 Mar; 37(2):726-8. PubMed ID: 15848514
[TBL] [Abstract][Full Text] [Related]
25. An ABO incompatible sibling as rescue kidney donor.
Blohmé I; Mjörnstedt L; Rydberg L; Nyberg G; Tufveson G
Transplant Proc; 1994 Jun; 26(3):1745. PubMed ID: 8030115
[No Abstract] [Full Text] [Related]
26. Early or delayed use of cyclosporine in HLA-mismatched living-related donor renal transplants.
Sumrani N; Hong JH; Daskalakis P; Cacciarelli TV; Markell MS; Sommer BG
Transplant Proc; 1993 Jun; 25(3):2246-7. PubMed ID: 8516888
[No Abstract] [Full Text] [Related]
27. The UNOS Scientific Renal Transplant Registry.
Cecka JM
Clin Transpl; 1999; ():1-21. PubMed ID: 11038622
[TBL] [Abstract][Full Text] [Related]
28. Kidney transplantation by use of splenectomy and transfusions, cadaver haplotype matching, suppressor cell assays, and T-cell monitoring.
Severyn W; Kyriakides G; Fuller L; Esquenazi V; Flaa C; Olson L; Goldsmith C; Miller J
Surgery; 1981 Aug; 90(2):364-75. PubMed ID: 6454982
[TBL] [Abstract][Full Text] [Related]
29. A comparison of donor-specific and random transfusions in living-related renal transplantation and their effect on steroid withdrawal.
Reed A; Pirsch JD; Armbrust MJ; Burlingham WJ; Knechtle SJ; D'Alessandro AM; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1991 Feb; 23(1 Pt 2):1321-2. PubMed ID: 1989226
[No Abstract] [Full Text] [Related]
30. Effect of cyclosporine A on the outcome of one-haplotype identical kidney grafts from a living related donor.
Papadimitriou M; Vakianis P; Malliara M; Economidou D; Alexopoulos E; Belechri AM; Koukoudis P; Papadopoulou D; Syrganis C; Polymenidis Z
Transplant Proc; 1994 Oct; 26(5):2548-9. PubMed ID: 7940786
[No Abstract] [Full Text] [Related]
31. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
Saudi J Kidney Dis Transpl; 2008 Jul; 19(4):564-70. PubMed ID: 18580014
[TBL] [Abstract][Full Text] [Related]
32. Impact of HLA-identity on results of ABO-incompatible living kidney transplantation.
Shimmura H; Tanabe K; Tokumoto T; Ishida H; Ishikawa N; Miyamoto N; Shimizu T; Shirakawa H; Setoguchi K; Teraoka S; Toma H
Transplant Proc; 2004 Sep; 36(7):2172-4. PubMed ID: 15518790
[TBL] [Abstract][Full Text] [Related]
33. Living-unrelated renal transplantation at the University of Wisconsin.
Pirsch JD; D'Alessandro AM; Sollinger HW; Voss BJ; Knechtle SJ; Reed A; Kalayoglu M; Belzer FO
Clin Transpl; 1990; ():241-5. PubMed ID: 2103149
[TBL] [Abstract][Full Text] [Related]
34. Different trends in immunosuppression: 10 years' experience with cyclosporine after living related donor renal transplantation.
Bakr MA; Sally S; Foda MA; Sobh MA; el-Sherif AK; Ghoneim MA
Transplant Proc; 1994 Dec; 26(6):3163-6. PubMed ID: 7998104
[No Abstract] [Full Text] [Related]
35. Donor-specific flow cytometric cross-match after kidney transplantation.
Puig N; Pallardó LM; Villalba JV; Sánchez J; Crespo J; Rodriguez R; Montoro JA
Transplant Proc; 1995 Aug; 27(4):2369-70. PubMed ID: 7652842
[No Abstract] [Full Text] [Related]
36. Renal allograft survival in patients with positive donor-specific B lymphocyte crossmatches.
Noreen HJ; van der Hagen E; Bach FH; Fryd D; Ascher N; Simmons RL; Najarian JS
Transplant Proc; 1987 Feb; 19(1 Pt 1):780-1. PubMed ID: 3274873
[No Abstract] [Full Text] [Related]
37. Outcome of donor specific transfusion renal transplants across B cell positive crossmatches.
Balakrishnan K; Munda R; First MR; Alexander JW
Transplant Proc; 1989 Feb; 21(1 Pt 2):1836. PubMed ID: 2652597
[No Abstract] [Full Text] [Related]
38. Immunological monitoring of posttransplant allograft sensitization following living related donor renal transplantation.
Panigrahi A; Deka R; Bhowmik D; Tiwari SC; Mehra NK
Transplant Proc; 2004 Jun; 36(5):1336-9. PubMed ID: 15251326
[TBL] [Abstract][Full Text] [Related]
39. Renal allograft survival in CSA-treated patients with positive donor-specific B cell crossmatches.
Noreen HJ; van der Hagen E; Bach FH; Najarian JS; Fryd DS
Transplant Proc; 1989 Feb; 21(1 Pt 1):691-2. PubMed ID: 2650224
[No Abstract] [Full Text] [Related]
40. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
Shabtai M; Ben-Haim M; Zemer D; Malinger-Saavedra P; Rosin D; Kuriansky J; Lustig S; Shabtai EL; Shapira Z; Ayalon A
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
